Combining two types of inhibitors to improve treatment for Acute Myeloid Leukemia
Official title: Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
Funded at Oregon Health & Science University · NIH-10887555 · Data updated 2026-11-12
This study is looking at how two types of cancer-fighting drugs can work together to help people with Acute Myeloid Leukemia (AML) by blocking the genes that help cancer cells grow, with the goal of finding better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | July 13, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $488,445 |
| NIH project number | 5R01CA282133-02 |
| Project ID | NIH-10887555 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia, particularly those with FLT3 or NRAS mutations.
✕Less likely to help
Patients with other types of leukemia or those who do not have the specific mutations targeted by this research may not benefit.
What this research studies
This research investigates the combined effect of kinase inhibitors and LSD1 inhibitors on Acute Myeloid Leukemia (AML). The approach aims to understand how these drugs work together to suppress harmful gene expressions that promote cancer cell growth. By exploring the mechanisms behind this combination therapy, the research seeks to develop more effective treatment options for patients suffering from AML. The study will focus on specific mutations in the cancer cells to tailor the treatment effectively.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with Acute Myeloid Leukemia, potentially improving survival rates.
How similar studies have gone: While kinase inhibitors have been used in AML treatment, the combination with LSD1 inhibition is a novel approach that has not been extensively tested in clinical settings.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Braun, Theodore Paul — Oregon Health & Science University
- Study coordinator: Braun, Theodore Paul
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.